Details

Autor(en) / Beteiligte

• Li, Bryan K
• Vasiljevic, Alexandre
• Dufour, Christelle
• Yao, Fupan
• Ho, Ben LB
• Lu, Mei
• Hwang, Eugene I
• Gururangan, Sridharan
• Hansford, Jordan R
• Fouladi, Maryam
• Nobusawa, Sumihito
• Laquerriere, Annie
• Delisle, Marie-Bernadette
• Fangusaro, Jason
• Forest, Fabien
• Toledano, Helen
• Solano-Paez, Palma
• Leary, Sarah
• Birks, Diane
• Hoffman, Lindsey M
• Szathmari, Alexandru
• Faure-Conter, Cécile
• Fan, Xing
• Catchpoole, Daniel
• Zhou, Li
• Schultz, Kris Ann P
• Ichimura, Koichi
• Gauchotte, Guillaume
• Jabado, Nada
• Jones, Chris
• Loussouarn, Delphine
• Mokhtari, Karima
• Rousseau, Audrey
• Ziegler, David S
• Tanaka, Shinya
• Pomeroy, Scott L.
• Gajjar, Amar
• Ramaswamy, Vijay
• Hawkins, Cynthia
• Grundy, Richard G
• Hill, D Ashley
• Bouffet, Eric
• Huang, Annie
• Jouvet, Anne

Titel

Pineoblastoma segregates into molecular sub-groups with distinct clinicopathologic features: A Rare Brain Tumor Consortium registry study

Ist Teil von

• Acta neuropathologica, 2019-12, Vol.139 (2), p.223-241

Erscheinungsjahr

2019

Quelle

SpringerLink

Beschreibungen/Notizen

• Pineoblastoma (PB) are rare, aggressive pediatric brain tumors of the pineal gland with modest overall survival despite intensive therapy. We sought to define the clinical and molecular spectra of PB to inform new treatment approaches for this orphan cancer. Tumor, blood, and clinical data from 91 patients with PB or supratentorial primitive neuroectodermal tumor (sPNETs/CNS-PNETs), and 2 pineal parenchymal tumors of intermediate differentiation (PPTIDs) were collected from 29 centres in the Rare Brain Tumor Consortium. We used global DNA methylation profiling to define a core group of PB from 72/93 cases, which were delineated into five molecular subgroups. Copy number, whole exome and targeted sequencing, and miRNA expression analyses were used to evaluate the clinico-pathologic significance of each subgroup. Tumors designated as group 1 and 2 almost exclusively exhibited deleterious homozygous loss of function alterations in miRNA biogenesis genes ( DICER1 , DROSHA , and DGCR8 ) in 62 and 100% of group 1 and 2 tumors respectively. Recurrent alterations of the oncogenic MYC-miR-17/92-RB1 pathway were observed in the RB and MYC subgroup, respectively characterized by RB1 loss with gain of miR-17/92 , and recurrent gain or amplification of MYC . PB sub-groups exhibited distinct clinical features: group 1-3 arose in older children (median ages 5.2-14.0 years) and had intermediate to excellent survival (5-year OS of 68.0-100%), while Group RB and MYC PB patients were much younger (median age 1.3-1.4 years) with dismal survival (5-year OS 37.5% and 28.6%, respectively). We identified age <3 years at diagnosis, metastatic disease, omission of upfront radiation, and chr 16q loss as significant negative prognostic factors across all PBs. Our findings demonstrate that PB exhibit substantial molecular heterogeneity with sub-group associated clinical phenotypes and survival. In addition to revealing novel biology and therapeutics, molecular sub-grouping of PB can be exploited to reduce treatment intensity for patients with favorable biology tumors.